1. Home
  2. OIG vs STTK Comparison

OIG vs STTK Comparison

Compare OIG & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OIG

Orion180 Insurance Group Inc. Class A common stock

N/A

Current Price

$9.05

Market Cap

582.7M

Sector

N/A

ML Signal

N/A

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.03

Market Cap

652.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OIG
STTK
Founded
2018
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
582.7M
652.4M
IPO Year
2026
2020

Fundamental Metrics

Financial Performance
Metric
OIG
STTK
Price
$9.05
$6.03
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
★ $15.40
AVG Volume (30 Days)
665.0K
★ 1.5M
Earning Date
11-22-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 53.02
EPS
★ N/A
N/A
Revenue
N/A
★ $1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$7.78
$1.70
52 Week High
$12.06
$8.33

Technical Indicators

Market Signals
Indicator
OIG
STTK
Relative Strength Index (RSI) 32.93 43.83
Support Level $7.78 $5.85
Resistance Level $10.55 $7.83
Average True Range (ATR) 0.87 0.47
MACD -0.07 -0.03
Stochastic Oscillator 45.21 33.24

Price Performance

Historical Comparison
OIG
STTK

About OIG Orion180 Insurance Group Inc. Class A common stock

Orion180 Insurance Group Inc operating as an insurance holding company. It is a founder-led, technology-focused, high-growth, high-margin specialty insurance group delivering insurance solutions with a growing footprint across the United States. The group operates in two segments: Services and Underwriting. The Services segment includes technology-enabled policy servicing operations, including intercompany revenue earned through service arrangements between the Services and Underwriting segments. The Underwriting segment includes a conventional, regulated insurance model focused on risk selection, pricing, and statutory capital management. The segment also includes a segregated cell designed to assume reinsurance risk.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: